These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 2033963)
1. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Cuttner J; Mick R; Budman DR; Mayer RJ; Lee EJ; Henderson ES; Weiss RB; Paciucci PA; Sobol R; Davey F Leukemia; 1991 May; 5(5):425-31. PubMed ID: 2033963 [TBL] [Abstract][Full Text] [Related]
2. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. Ellison RR; Mick R; Cuttner J; Schiffer CA; Silver RT; Henderson ES; Woliver T; Royston I; Davey FR; Glicksman AS J Clin Oncol; 1991 Nov; 9(11):2002-15. PubMed ID: 1941059 [TBL] [Abstract][Full Text] [Related]
3. [Clinical trial of protocol-AL851 for children with high-risk acute lymphoblastic leukemia. Kyushu Yamaguchi Children's Cancer Study Group (KYCCSG)]. Matsuzaki A; Ishii E; Ueda K; Yanai F; Nibu K; Take H; Koga H; Miyazaki S; Inoue T; Miyake K Rinsho Ketsueki; 1994 Sep; 35(9):862-70. PubMed ID: 7967055 [TBL] [Abstract][Full Text] [Related]
4. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507 [TBL] [Abstract][Full Text] [Related]
5. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E; Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744 [TBL] [Abstract][Full Text] [Related]
6. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials. Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy. Lemez P; Maresová J Semin Oncol; 1998 Aug; 25(4 Suppl 10):61-5. PubMed ID: 9768826 [TBL] [Abstract][Full Text] [Related]
8. Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. Falletta JM; Shuster JJ; Crist WM; Pullen DJ; Borowitz MJ; Wharam M; Patterson R; Foreman E; Vietti TJ Leukemia; 1992 Jun; 6(6):541-6. PubMed ID: 1602793 [TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Lange BJ; Blatt J; Sather HN; Meadows AT Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG). van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546 [TBL] [Abstract][Full Text] [Related]
11. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study. Miyawaki S; Sakamaki H; Ohtake S; Emi N; Yagasaki F; Mitani K; Matsuda S; Kishimoto Y; Miyazaki Y; Asou N; Matsushima T; Takahashi M; Ogawa Y; Honda S; Ohno R; Cancer; 2005 Dec; 104(12):2726-34. PubMed ID: 16284985 [TBL] [Abstract][Full Text] [Related]
12. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study. Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M; Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410 [TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638 [TBL] [Abstract][Full Text] [Related]
14. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906 [TBL] [Abstract][Full Text] [Related]
15. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U; J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786 [TBL] [Abstract][Full Text] [Related]
16. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi A; Miniero R; Di Tullio MT; Lo Nigro L; Pession A; Rondelli R; Messina C; Santoro N; Mori PG; De Rossi G; Tamaro P; Silvestri D; Biondi A; Basso G; Masera G Haematologica; 1998 Sep; 83(9):791-9. PubMed ID: 9825576 [TBL] [Abstract][Full Text] [Related]
17. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809 [TBL] [Abstract][Full Text] [Related]
18. Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia. Lee SM; Lee WS; Shin HJ; Lee JJ; Sohn SK; Moon JH; Eom HS; Won JH; Lee KH; Lee JH; Kim DY; Yoon SS; Kim I; Jung CW; Kim SJ; Kim H; Lee JH; Ryoo HM; Lee GW; Kim SH; Mun YC; Kim MK; Joo YD; Ann Hematol; 2013 Aug; 92(8):1101-10. PubMed ID: 23558905 [TBL] [Abstract][Full Text] [Related]
19. Acute myeloid and lymphoblastic leukemia in adults. The course of the disease in 315 patients from one region, during a ten-year period. Johnsen HE; Bergmann OJ; Ellegaard J; Bastrup-Madsen P Dan Med Bull; 1989 Apr; 36(2):189-93. PubMed ID: 2707057 [TBL] [Abstract][Full Text] [Related]
20. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]